Insulin glargine and cancer: another side to the story?

被引：20

作者：

Gale, Edwin A. M. ^{[1
]}

机构：

[1] Southmead Hosp, Med Sch Unit, Bristol BS10 5NB, Avon, England

来源：

LANCET | 2009年 / 374卷 / 9689期

关键词：

D O I：

10.1016/S0140-6736(09)61477-X

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：521 / 521

页数：1

共 7 条

[1]

CURRIE CJ, 2009, DIABETOLOGIA

[2] Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues: a cohort study [J].

Hemkens, L. G. ;

Grouven, U. ;

Bender, R. ;

Guenster, C. ;

Gutschmidt, S. ;

Selke, G. W. ;

Sawicki, P. T. .

DIABETOLOGIA, 2009, 52 (09) :1732-1744

[3] Insulin glargine use and short-term incidence of malignancies-a population-based follow-up study in Sweden [J].

Jonasson, J. M. ;

Ljung, R. ;

Talback, M. ;

Haglund, B. ;

Gudbjornsdottir, S. ;

Steineck, G. .

DIABETOLOGIA, 2009, 52 (09) :1745-1754

[4] Insulin glargine and malignancy: an unwarranted alarm [J].

Pocock, Stuart J. ;

Smeeth, Liam .

LANCET, 2009, 374 (9689) :511-513

[5]

*SCOTT DIAB RES NE, 2009, DIABETOLOGIA

[6] Does diabetes therapy influence the risk of cancer? [J].

Smith, U. ;

Gale, E. A. M. .

DIABETOLOGIA, 2009, 52 (09) :1699-1708

[7]

2009, SANOFI AVENTIS EXPER

← 1 →